Tilhørighet
Publikasjoner og forskningsresultater
Vitenskapelige publikasjoner (11)
- Lønning, Per Eystein; Berge, Elisabet Ognedal; Bjørnslett, Merete Pauline; Minsaas, Laura; Chrisanthar, Ranjan; Vetti, Hildegunn Høberg; Dulary, Cécile; Busato, Florence; Bjørneklett, Silje; Eriksen, Christine; Kopperud, Reidun Kristin; Axcrona, Ulrika; Davidson, Ben; Bjørge, Line; Evans, D. Gareth; Howell, Anthony; Salvesen, Helga; Janszky, Imre; Hveem, Kristian; Romundstad, Pål Richard; Vatten, Lars Johan; Tost, Jörg; Dørum, Anne; Knappskog, Stian (2018). White blood cell BRCA1 promoter methylation status and ovarian cancer risk. Annals of Internal Medicine. Vol. 168. s. 326-334
- Yndestad, Synnøve; Austreid, Eilin; Knappskog, Stian; Chrisanthar, Ranjan; Lilleng, Peer Kåre; Lønning, Per Eystein; Eikesdal, Hans Petter (2017). High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function. Breast Cancer Research and Treatment. Vol. 163. s. 177-190
- Knappskog, Stian; Berge, Elisabet Ognedal; Chrisanthar, Ranjan; Geisler, Stephanie; Staalesen, Vidar; Leirvaag, Beryl; Yndestad, Synnøve; Faveri, Elise Norheim de; Karlsen, Bård Ove; Wedge, David C.; Akslen, Lars A.; Lilleng, Peer Kåre; Løkkevik, Erik; Lundgren, Steinar; Østenstad, Bjørn; Risberg, Terje; Mjaaland, Ingvil; Aas, Turid; Lønning, Per Eystein (2015). Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo. Molecular Oncology. Vol. 9. s. 1553-1564
- Knappskog, Stian; Chrisanthar, Ranjan; Løkkevik, Erik; Anker, Gun Birgitta; Østenstad, Bjørn; Lundgren, Steinar; Risberg, Terje; Mjaaland, Ingvil; Leirvaag, Beryl; Miletic, Hrvoje; Lønning, Per Eystein (2012). Low expression levels of ATM may substitute for CHEK2/TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer. Breast Cancer Research. Vol. 14
- Chrisanthar, Ranjan; Knappskog, Stian; Løkkevik, Erik; Anker, Gun Birgitta; Østenstad, Bjørn; Lundgren, Steinar; Risberg, Terje; Mjaaland, Ingvil; Skjønsberg, Gudbrand; Aas, Turid; Schlichting, Ellen; Fjøsne, Hans Erikssønn; Nysted, Arne; Lillehaug, Johan R.; Lønning, Per Eystein (2011). Predictive and Prognostic Impact of TP53 Mutations and MDM2 Promoter Genotype in Primary Breast Cancer Patients Treated with Epirubicin or Paclitaxel. PLOS ONE. Vol. 6
- Knappskog, Stian; Bjørnslett, Merete Pauline; Myklebust, Line Merethe; Huijts, Petra E.A.; Vreeswijk, Maaike P.; Edvardsen, Hege; Guo, Yongli; Zhang, Xuemei; Yang, Ming; Ylisaukko-oja, Sanna K.; Alhopuro, Pia; Arola, Johanna; Tollenaar, Rob A.E.M.; Asperen, Christi J van; Seynaeve, Caroline; Staalesen, Vidar; Chrisanthar, Ranjan; Løkkevik, Erik; Salvesen, Helga Birgitte; Evans, D. Gareth; Newman, William G.; Lin, Dongxin; Aaltonen, Lauri; Børresen-Dale, Anne-Lise; Tell, Grethe S; Stoltenberg, Camilla; Romundstad, Pål Richard; Hveem, Kristian; Lillehaug, Johan R.; Vatten, Lars Johan; Devilee, Peter; Dørum, Anne; Lønning, Per Eystein (2011). The MDM2 Promoter SNP285C/309G Haplotype Diminishes Sp1 Transcription Factor Binding and Reduces Risk for Breast and Ovarian Cancer in Caucasians. Cancer Cell. Vol. 19. s. 273-282
- Chrisanthar, Ranjan; Knappskog, Stian; Løkkevik, Erik; Anker, Gun Birgitta; Østenstad, Bjørn; Lundgren, Steinar; Berge, Elisabet Ognedal; Risberg, Terje; Mjaaland, Ingvil; Mæhle, Lovise Olaug; Engebretsen, Lars Fredri; Lillehaug, Johan; Lønning, Per Eystein (2008). CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer. PLOS ONE. Vol. 3:e0003062
- Lønning, Per Eystein; Chrisanthar, Ranjan; Staalesen, Vidar; Knappskog, Stian; Lillehaug, Johan (2007). Adjuvant treatment: the contribution of expression microarrays. Breast Cancer Research. Vol. 9
- Lønning, Per Eystein; Knappskog, Stian; Staalesen, Vidar; Chrisanthar, Ranjan; Lillehaug, Johan (2007). Breast cancer prognostication and prediction in the postgenomic era. Annals of Oncology. Vol. 18. s. 1293-1306
- Knappskog, Stian; Chrisanthar, Ranjan; Staalesen, Vidar; Borresen-Dale, AL; Børresen-Dale, Anne-Lise; Gram, Inger Torhild; Lillehaug, Johan Richard; Lonning, PE; Lønning, Per Eystein (2007). Mutations and polymorphisms of the p21B transcript in breast cancer. International Journal of Cancer. Vol. 121. s. 908-910
- Stålesen, Vidar; Staalesen, Vidar; Knappskog, Stian; Chrisanthar, Ranjan; Nordgard, Silje H; Nordgard, Silje H.; Løkkevik, Erik; Anker, Gun; Østenstad, Bjørn; Lundgren, Steinar; Risberg, Terje; Mjåland, Ingvil; Mjaaland, Ingvil; Gram, Inger Torhild; Kristensen, Vessela N; Børresen-Dale, Anne-Lise; Lillehaug, Johan Richard; Lønning, Per Eystein (2006). The novel p21 polymorphism p21(G251A) is associated with locally advanced breast cancer. Clinical Cancer Research. Vol. 12. s. 6000-6004
Forskningsrapporter (1)
- Chrisanthar, Ranjan (2009). Resistance to Chemotherapy in Breast Cancer: Potential role of p21B, p27 and the p53 apoptotic pathway. Universitetet i Bergen
Formidling (8)
- Ersvær, Elisabeth; Lie-Jensen, Anette Christensen; Chrisanthar, Ranjan; Neslein, Inger-Lise F.; Solli, Ann Iren; Alm, Bente; Wergeland, Line; Bach, Ragnhild (2025). Bioingeniører må være med å utdanne morgendagens bioingeniører - med hvordan rekrutterer vi dem?. s. 26-29
- Chrisanthar, Ranjan (2009). 1. CHEK2 mutations affecting kinase activity together with mutations in TP53 indicates a functional pathway associated with resistance to epirubicin in primary breast cancer. Forskerskolen i klinisk medisin
- Chrisanthar, Ranjan (2008). Genforandringer som årsak til kjemoresistans ved primær brystkreft
- Chrisanthar, Ranjan (2008). CHEK2 mutations affecting kinase activity together with mutations in TP53 indicates a functional pathway associated with resistance to epirubicin in primary breast cancer. 9th Bergen Conference on Cancer Research 2008
- Chrisanthar, Ranjan (2008). Betydningen av mutasjoner i CHEK2 genet i tillegg til TP53 mutasjoner for resistens mot epirubicin. Onkologisk Forum, Bergen, November 20-21, 2008
- Chrisanthar, Ranjan; Knappskog, Stian; Staalesen, Vidar; Lillehaug, Johan; Lønning, Per Eystein (2007). P21/waf1 mutation and drug resistance to paclitaxel in locally advanced breast cancer. International Journal of Cancer. Vol. 120. s. 2749-2749
- Staalesen, Vidar; Knappskog, Stian; Chrisanthar, Ranjan; Geisler, Stephanie; baumbusch, lars; Løkkevik, Erik; Østenstad, Bjørn; Geisler, Jurgen; Børresen-Dale, Anne-Lise; Lillehaug, Johan; Lønning, Per Eystein (2007). The MDM2 SNP309 G/T promoter polymorphism is associated with chemoresistance in primary breast cancers harbouring mutations in the TP53 gene. AACR annual meeting
- Chrisanthar, Ranjan (2006). Genforandringer som årsak til kjemoresistans ved primær brystkreft
Publikasjonslisten er hentet ut av Nasjonalt vitenarkiv (NVA). Listen kan være ufullstendig.